Thelial is dedicated to epithelia
Thelial is exclusively dedicated to epithelial indications
- carcinoma (especially non-melanoma skin cancer).
- epithelial barrier defects (initial focus orphan allergy indication).
The mechanism of action we exploit is cell polarity modulation: Healthy cells are polar, loss of cell polarity is linked to disease and ageing – Thelial focuses on discovery and development of polarity modulating compounds to address mayor unmet market needs.
theLiTE™ (Thelial – Live Targeted Epithelia) is our proprietary targeted drug discovery platform technology; screening a library of more than 2000 drug candidates we have discovered more than twenty epithelium targeted candidates, validating theLiTE™. Please request a non-confidential presentation on out technology and portfolio.For more information contact us